Table 1.
Selected trials of oligoprogressive NSCLC patients treated with local ablative therapies combined with TKI.
| Author (Year) | Type of Study | N. of Patients | Molecular Status | LAT | Sites | mPFS (Months) | mOS (Months) |
|---|---|---|---|---|---|---|---|
| Weickhardt et al. (2012) [9] |
Retrospective | 25 | EGFR+, ALK+ (54%) | SBRT, SRS, WBRT, XRT, surgery | CNS + eCNS | 6.2 * | - |
| Gan et al. (2014) [22] |
Retrospective | 14 | ALK+ (100%) | SBRT, HRT, surgery | eCNS | 5.5 * | 39 |
| Liu et al. (2018) [23] |
Retrospective | 38 | ALK+ (86.8%), ROS1+ | SBRT, WBRT | CNS + eCNS | 9.9 * | - |
| Kroeze et al. (2021) [24] |
Retrospective | 108 | EGFR+, ALK+ (15%), ROS1+, WT | SRS, SBRT | CNS + eCNS | 10.4 | - |
| Borghetti P et al. (2019) [25] |
Retrospective | 106 | EGFR+, ALK+ (19%) | SRT, HRT | CNS + eCNS | - | 23 |
| Ni et al. (2019) [26] |
Retrospective | 19 | ALK+ (100%) | SBRT, SRS, WBRT | CNS + eCNS | 10 * | - |
| Takeda et al. (2013) [27] |
Retrospective | 7 | ALK+ (100%) | WBRT, SRS | CNS | 5.5 * | - |
LAT: local ablative therapy; mPFS: median progression-free survival; mOS: median overall survival; TKI: tyrosine kinase inhibitor; HRT: hypofractionated radiotherapy; SBRT: stereotactic body radiation therapy; SRS: stereotactic radiosurgery; XRT: standard radiation therapy; SRT: stereotactic radiotherapy; WT: wild-type; CNS: central nervous system; eCNS: extra-CNS. * Calculated from progression on TKI. The Kroesze et al. study included both oligoprogressive (≤5 metastatic sites) and polyprogressive (>5 metastatic sites) patients. In oligoprogressive patients (56%) mPFS was 10.4 months. The Ni et al. study included both oligoprogressive/oligometastatic (≤4 metastatic sites) and polyprogressive (>5 metastatic sites) patients. Fifty-two patients were defined as oligometastatic/oligoprogressive. SRT with an ablative intent was administered in 49 patients.